Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for cellular electrolyte balance, essential for nerve conduction, muscle contraction, and acid-base homeostasis. Dextrose acts as a caloric source, and sodium chloride provides sodium and chloride ions for fluid and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Correction of hypokalemia,Maintenance of electrolyte and fluid balance,Caloric supply in parenteral nutrition
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion. Dose determined by electrolyte needs; typical maintenance: 1000-2000 m L/day (providing 20-40 m Eq potassium, 50-100 g dextrose, and 77-154 m Eq sodium). Rate not to exceed 10 m Eq/hour potassium.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal elimination half-life of potassium is not well-defined as a single value due to rapid distribution kinetics. However, whole-body turnover half-life is approximately 12-24 hours. Clinically, redistribution half-life from plasma to cells is about 1-2 hours, while total body elimination depends on renal function.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to carbon dioxide and water, providing energy. Sodium and chloride are excreted mainly via kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Potassium is primarily excreted renally (approximately 90%), with about 10% eliminated via feces. Under normal conditions, the kidneys excrete 40-120 m Eq/day of potassium, with excretion closely matched to intake. Biliary excretion is negligible.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Potassium is not significantly bound to plasma proteins; protein binding is approximately 0%. It exists as free ions.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Volume of distribution for potassium is 0.5-0.7 L/kg (average 0.6 L/kg), reflecting total body water. Clinical meaning: Potassium distributes mainly in the intracellular space (98% of total body potassium) with only 2% in extracellular fluid; thus, changes in serum levels poorly reflect total body stores. The Vd is used to calculate loading doses for replacement therapy.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: Potassium chloride is well absorbed from the gastrointestinal tract with an oral bioavailability of approximately 90-100%. Intravenous: 100% bioavailability.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) unless carefully monitored. For GFR 30-50 m L/min: reduce dose by 50% and monitor potassium levels. For GFR >50 m L/min: no adjustment typically needed.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment for Child-Pugh class A or B. For Class C (severe hepatic impairment): use with caution due to risk of electrolyte disturbances; monitor potassium and glucose levels.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Dose based on weight and electrolyte requirements. Typical starting infusion: 0.5-1 m Eq/kg/day potassium (as part of fluid). Rate not to exceed 0.5 m Eq/kg/hour. Monitor serum potassium and glucose.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Initiate at lower end of dosing range due to potential renal function decline. Monitor renal function, serum potassium, and glucose closely. Avoid rapid infusion; maximum rate 10 m Eq/hour potassium.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Concentrated potassium chloride solutions (e.g., >0.1% KCl) must be diluted before administration to avoid fatal hyperkalemia. This product contains 0.075% KCl and is not concentrated, but caution is still required.
None
Monitor serum potassium levels to avoid hyperkalemia; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Administer via compatible intravenous line; do not add medications to the plastic container. Check for air embolism risk.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia, severe renal failure with oliguria or anuria, untreated Addison's disease, concomitant use of potassium-sparing diuretics, acute dehydration, heat cramps, and conditions where potassium administration is contraindicated.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid excessive dietary potassium (e.g., bananas, potatoes, tomatoes, spinach, salt substitutes) during treatment to prevent hyperkalemia. No other significant food interactions.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Potassium chloride is a physiologic ion. No teratogenic effects have been associated with potassium chloride administration at recommended doses. However, hyperkalemia or hypokalemia may adversely affect fetal development. First trimester: no specific risk; second and third trimesters: risk only if maternal electrolyte disturbances occur.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Potassium is a normal constituent of breast milk. Supplemental potassium chloride is considered compatible with breastfeeding. No M/P ratio available; potassium levels in milk are regulated and unlikely to be affected by maternal supplementation except in overdose.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustment required for potassium chloride itself. However, pregnancy increases plasma volume and renal blood flow, which may alter potassium requirements. Monitor serum potassium and adjust dose based on levels. Dextrose component may require adjustment in gestational diabetes.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This solution provides 10 m Eq/L potassium, 5% dextrose, and 0.11% sodium chloride (19 m Eq/L Na). Use for maintenance or replacement when mild potassium deficits coexist with carbohydrate and sodium needs. Avoid rapid infusion; rate should not exceed 10-20 m Eq/h potassium. Contraindicated in severe renal impairment, hyperkalemia, or Addison's disease. Monitor serum potassium, glucose, and renal function.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This infusion contains potassium, dextrose (sugar), and salt.,Report any chest pain, shortness of breath, or irregular heartbeat immediately.,May cause discomfort at IV site; notify nurse if redness or swelling occurs.,Avoid additional potassium supplements (foods like bananas, orange juice) unless advised.,Do not stop or adjust the infusion rate.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for cellular electrolyte balance, essential for nerve conduction, muscle contraction, and acid-base homeostasis. Dextrose acts as a caloric source, and sodium chloride provides sodium and chloride ions for fluid and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion. Dose determined by electrolyte needs; typical maintenance: 1000-2000 m L/day (providing 20-40 m Eq potassium, 50-100 g dextrose, and 77-154 m Eq sodium). Rate not to exceed 10 m Eq/hour potassium.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride is a physiologic ion. No teratogenic effects have been associated with potassium chloride administration at recommended doses. However, hyperkalemia or hypokalem. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.